Background: Postneurosurgical Gram-negative bacillary meningitis (GNBM) or ventriculitis is a serious issue. Intraventricular (IVT) therapy has been applied; however, its effectiveness remains controversial, and the adverse drug effects are considerable. Methods: The demographic data, treatment strategies, and clinical outcomes of patients with postneurosurgical GNBM or ventriculitis were recorded. Results: From 2003 to 2011, data on 127 episodes of infection in 109 patients were collected, and 15 episodes in 14 patients were treated using a sequential combination of intravenous antibiotics and IVT therapy; others received intravenous antibiotics alone. The average age of patients who received a sequential combination with IVT therapy was 48.9 years, and 71.4% of the patients were men. The regimens used for IVT therapies included gentamicin (n Z 4), amikacin (n Z 7), and colistin (n Z 4). After meningitis had been diagnosed, the average period that elapsed before initiation of IVT therapy was 25.4 days, and the average duration of IVT therapy was 13.3 days. The most frequently isolated pathogen from cerebrospinal fluid (CSF) was Acinetobacter baumannii, followed by Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Serratia marcescens. The cure rate was 73.3%. Available online at www.sciencedirect.com j ourna l home pa ge: www.e-jmii.com
Introduction
Nosocomial postneurosurgical meningitis is a serious medical issue, particularly in patients with Gram-negative bacillary infection. 1 There is an increasing incidence of postneurosurgical meningitis; this has risen from 12% to 27% of all cases of bacterial meningitis, 2 and the overall mortality for Gram-negative bacillary meningitis (GNBM) has been reported to be high. 1, 3 Furthermore, the treatment strategies for GNBM or ventriculitis have become more complex. Multiple bacteria with reduced sensitivity to antibiotics have been emerging 4, 5 ; moreover, there are limitations to antimicrobial concentrations at the sites of infection. 6 Thus, a combination of intravenous (IV) and intraventricular (IVT) antibiotic administration may be one choice to ensure sterilization of the cerebrospinal fluid (CSF) while minimizing adverse drug effects. 7 The use of IVT antimicrobial agents remains a challenging intervention due to limited evidence for the efficacy and safety of this treatment. McCracken et al demonstrated a threefold increased relative risk for mortality. 8 Conversely, some studies have reported an overall cure rate of 80% with IVT polymyxins 9 and 100% for those with IVT gentamicin. 10, 11 In terms of the controversial option of employing IVT therapy for GNBM, there have been few well-designed studies and clinical trials to verify IVT therapy among adult populations.
In this study, we report our experience with IVT antibiotic therapy in 15 episodes of postneurosurgical GNBM or ventriculitis, and we also made a comparison of the clinical and laboratory data and therapeutic results between patients receiving IVT therapy and those with IV antibiotic treatment alone.
Methods

Patients and setting
From January 2003 to October 2011, we enrolled patients who experienced complications including GNBM and ventriculitis following neurosurgical procedures at the China Medical University Hospital, a 2000-bed medical center in Taiwan. Patients were included when all of the following criteria were met: (1) isolation of Gram-negative bacilli from the CSF, (2) a CSF neutrophil count of >10 cells/mL, (3) clinical features of bacterial central nervous system (CNS) infection (at least one episode of temperature >37.5 C, headache, or neck stiffness), and (4) neurosurgery within the preceding 2 months. 10 A second episode of meningitis was considered a recurrence if it was due to a organism different from the one causing the initial episode or if it was due to the same organism occurring more than 3 weeks after completion of treatment for the initial episode.
12
All patients were treated empirically with IV antibiotics, and antibiotic treatment was later adjusted according to the culture report. The CSF analysis and culture were repeated once or twice every week until the CSF culture was negative or until the patient was discharged. Revision or removal of intracranial devices such as external ventricular drainage, a ventriculoperitoneal shunt, or an Ommaya reservoir was decided by the doctor in charge. 7 For patients with persistent bacterial growth in CSF cultures or clinical failure, sequential combination with IVT therapy was undertaken according to procedures outlined in previous studies 7, 10, 11, 15, 19 and the practice guidelines of the Infectious Diseases Society of America. 13 All patients were followed up for more than 3 months after completion of antimicrobial treatment. Medical charts were thoroughly reviewed, and any event of IVT therapy-related adverse drug effects was recorded.
Definitions
Mixed infection was defined as a patient having two or more bacterial organisms isolated from the initial CSF cultures. 14 Co-infection was defined as a patient having GNBM or ventriculitis with a simultaneous additional infection.
Efficacy was evaluated by both clinical and bacteriologic responses to therapy. In the treatment period, clinical failure was considered to be presentation with deteriorating clinical and laboratory signs of meningitis during appropriate antimicrobial therapy. For the clinical outcome, treatment failure was defined as death due to meningitis, or relapse. 10 Death was considered to be not due to meningitis if all of the following criteria were met: (1) resolving inflammatory parameters; (2) resolution of the clinical signs of meningitis; (3) a serious illness other than meningitis determined to be a more probable cause according to the treating physician; (4) completion of the antibiotic treatment before death; and (5) two negative CSF culture results (if performed) before death as modified by the criteria proposed by Durand et al. 12 Relapse was defined as isolation of the same organism from the CSF or from a CNS lesion within 3 weeks of completing therapy for the initial episode. 12 The criteria for cure proposed by Briggs et al. 3 were modified as follows: resolution of clinical and laboratory signs of meningitis; negative CSF culture results (if performed); and no relapse after withdrawal of antibiotics. We considered chemical ventriculitis to be present if the white blood cell count in the CSF rose with clinical improvement during IVT therapy. 15 Appropriate antimicrobial therapy was defined as the isolated bacteria being susceptible in vitro to the antimicrobial agents with an ability to achieve potentially therapeutic levels. 16 The period to CSF sterilization was counted from the day when appropriate IV or IVT antibiotic treatment was commenced to the day of the first negative CSF culture report after treatment. The elapsed period was calculated from the day when bacteria were first isolated in the CSF specimen to the day when IVT therapy was initiated.
Microbiology
The CSF specimens were streaked on Trypticase soy agar containing 5% sheep blood (TSA II) 
Results
From January 2003 to October 2011, there were 301 episodes of culture-proven bacterial meningitis at the China Medical University Hospital. Of these, 249 episodes occurred in patients involved in 16,725 neurosurgical procedures. In total, 127 episodes of GNBM or ventriculitis in 109 patients who fulfilled the criteria were included in this study. Table 1 summarizes the demographical data, clinical and laboratory findings, and therapeutic outcomes for these episodes. Fifteen episodes in 14 patients were treated using a sequential combination of IV and IVT therapy, and patients were followed up for more than 3 months. The remaining 112 episodes in 95 patients were treated using IV antibiotics only.
There was no significant difference in the demographic data, except length of hospital stay, between the patients treated with a sequential combination including IVT therapy and those who received IV antibiotics only. Among the 15 episodes that were treated using a sequential combination of IV and IVT antibiotics, the cure rate was 73.3% (11/15). All four nonsurviving patients died within 2 weeks after completion of therapy. Of these, two had more than two negative CSF culture results before death; however, the treating physician determined that meningitis was the only serious illness that could have been a more probable cause.
The causative organisms isolated from CSF culture are listed in Table 2 , and the antimicrobial resistance of the pathogens is listed in Table 3 . Among the episodes treated using sequential combination with IVT therapy, two patients (14.3%) had mixed infections, one showed methicillin-resistant Staphylococcus aureus, and the other was haboring Candida tropicalis. In terms of the causative organism, six episodes involving carbapenem-resistant A. baumannii (40.0%) and one episode involving carbapenem-resistant P. aeruginosa (6.7%) were seen. By contrast, there were more Enterobacteriaceae organisms, especially K. pneumoniae, in patients who received IV antibiotics alone (41.8% versus 26.7%). Table 4 details the clinic characteristics, microorganisms, antibiotic treatment, and outcome for 15 IVT episodes in 14 patients with postneurosurgical GNBM or ventriculitis. The regimens used for IVT therapies were diverse and included amikacin (n Z 7), gentamicin (n Z 4), and colistin (n Z 4). All IVT antibiotics were administered once daily and had in vitro activity against pathogens isolated from CSF. The daily IVT antibiotic dosage and duration varied. IVT therapy was added sequentially because of persistent bacterial growth in the CSF cultures (n Z 13) or as a result of clinical failure (n Z 2). The elapsed period from when bacteria were first isolated in the CSF specimens to the initiation of IVT therapy was 25.4 AE 17.6 (range 5e63) days, and the average duration of IVT therapy was 13.3 AE 6.7 (range 3e27) days. In this study, no adverse drug effects, seizures, or chemical ventriculitis were observed during the IVT therapy. Of the four patients in the IVT therapy group who died, P. aeruginosa infection was the most common, accounting for 75% (3/4) of instances. By contrast, the mortality rate was 42.9% (12/28) for all cases of P. aeruginosa causing CNS infection in this study.
Discussion
Mortality and morbidity rates for GNBM or ventriculitis in postneurosurgical patients remain unfavorably high. 1, 3 To optimize antimicrobial concentrations in CSF, IVT therapy should be considered for patients infected with drugresistant microorganisms or with those it is hard to eradicated. 7,9e11 However, clinicians have previously been wary of the IVT treatment modality because of concerns about IVT treatment-related adverse drug effects; careful preparation and delivery are required to avoid contamination. In addition, the effectiveness of IVT antibiotics in bacterial meningitis is controversial, and this treatment is often reserved for either seriously ill or treatment-refractory patients.
In this study, we analyzed 127 episodes of GNBM or ventriculitis in 109 patients who received neurosurgical procedures over an 8-year period. The cure rate for patients who received a sequential combination with IVT therapy in our study was similar to those observed in previous studies, which ranged from 71.4% to 100%. 7, 10, 11, 15, 19 In the present study, IVT therapy was added sequentially for patients with persistent bacterial growth in CSF cultures or who exhibited clinical failure. The findings of this study suggest that IVT antibiotic use in postneurosurgical GNBM or ventriculitis treatment may be able to shorten the period to CSF sterilization, especially in those with a treatmentrefractory state. This is important, because delayed sterilization of the CSF is associated with adverse neurologic outcomes. 20 Conversely, the mean period that elapsed before the initiation of IVT therapy in our study was much longer than that in previous studies. 10, 19 These variations in the time of addition of IVT therapy to systemic antibiotic treatment may be related to the variable mortality rate in those studies. 19 For this reason and because of the bacteriological cure rate for the patients in this study, we suggest that timely implementation of effective IVT therapy might increase the clinical cure rate for postneurosurgical GNBM or ventriculitis.
In the past, the major concern related to IVT therapy with antimicrobials was the possibility of adverse drug effects such as seizure, chemical ventriculitis, or hearing loss. 21 In the present study, hearing loss was not assessed because of the variable consciousness of these postneurosurgical patients. In previous reports, the incidence of these adverse effects varied from 13% to 60% for chemical a The denominator was set as episodes: n Z 15 for IV antibiotics plus sequential IVT therapy, and n Z 112 for IV antibiotics alone. b Intracranial hemorrhage related to traumatic brain injury was excluded. c Hydrocephalus or increased intracranial pressure without the above cause. BUN Z blood urea nitrogen; CNS Z central nervous system; CRP Z C-reactive protein; CSF Z cerebrospinal fluid; DM Z diabetes mellitus; ESR Z erythrocyte sedimentation rate; ESRD Z end-stage renal disease; ICH Z intracranial hemorrhage; IV Z intravenous; IVT Z intraventricular; PMN Z polymorphonuclear neutrophil granulocytes; RBC Z red blood cell; UTI Z urinary tract infection; WBC Z white blood cell.
ventriculitis, and from 4% to 20% for treatment-associated seizures. 15, 19 Several recent reports have suggested that the intrathecal or IVT administration of agents such as polymyxin B, colistin, and vancomycin is not associated with severe or irreversible adverse IVT drug effects. 21 Similarly, we report no incidents of seizure or chemical ventriculitis during IVT therapy. This indicates that IVT therapy is safe, but further well-designed studies are required to provide further evidence on this.
Of the causative organisms, the pathogens most frequently isolated from the CSF cultures in our study were Pseudomonas species (26.0%). This finding is similar to those of some studies, 2,17,18 whereas other reports have differed. 3, 16 Furthermore, we found that P. aeruginosa was the major cause of mortality in patients who received sequential combination with IVT therapy. Although this correlation has not been previously reported in adult populations, some studies have reported that P. aeruginosa is a predictor of unfavorable outcomes in neonates and children. 22, 23 For the above condition, we suggest that more aggressive interventions and earlier IVT therapy application for P. aeruginosa meningitis should be considered.
There are two limitations to this study. First, we did not enroll enough patients who had received a sequential combination of IV and IVT therapy to analyze the efficacy of IVT for different causative organisms. Second, with Mixed infection with methicillin-resistant Staphylococcus aureus. AIDS Z acquired immune deficiency syndrome; CR-Z carbapenem-resistant; DM Z diabetes mellitus; ESBL Z extended-spectrum beta-lactamase; EVD Z external ventricular drain; ICH Z intracranial hemorrhage; IV Z intravenous; s/p Z status post; TBI Z traumatic brain injury; VP shunt Z ventriculoperitoneal shunt. a retrospective study, it is difficult to define the optimal regimens, dosage, duration, and indications in IVT antimicrobial therapy for postneurosurgical patients with GNBM or ventriculitis. All of these would influence the treatment response to IVT therapy. For the above reasons and because of the high mortality rate among those who received IV antibiotic treatment alone for postneurosurgical GNBM, further large-scale prospective studies are needed.
In conclusion, this study details the clinical aspects of postneurosurgical GNBM or ventriculitis and outlines experiences of sequential combination with IVT therapy. The findings of this study suggest that IVT antibiotic use can be one of the options for postneurosurgical GNBM or ventriculitis treatment, especially for those with a treatmentrefractory state. Further prospective randomized studies are needed to determine whether this treatment modality could shorten the time to CSF sterilization, and thus improve patients' outcomes.
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